Active Clinical Trials

Combination Gene Transfer and Chemotherapy

By April 24, 2017 No Comments



Estimated Enrollment: 40

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: UPCC 02510; 811318

Study First Received: May 6, 2010

Last Updated: October 10, 2016

Estimated Primary Completion Date: October 2013


Primary Outcome Measures:

To determine the safety of administering intrapleural SCH 721015, Ad.hIFN-alpha2b (Adenoviral-mediated Interferon-alpha) in combination with chemotherapy for the management of MPM.|To estimate objective response rates and distribution|Time to Progression

Sponsors and Collaborators:

Abramson Cancer Center of the University of Pennsylvania

Website Link:

Leave a Reply

Call Now ButtonCall Now